Experience

SELLAS Life Sciences Group, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Commercial Officer (CCO)

  • Mar 2022 - Present

  Charged with building a comprehensive commercial infrastructure & capability with the end goal of successful commercialization of all portfolio products within solid tumors and hematologic malignancies. Serve as the key catalyst for the corporate transition from clinical stage to that of a revenue generating entity. Charged with building a comprehensive commercial infrastructure & capability with the end goal of successful commercialization of all portfolio products within solid tumors and hematologic malignancies. Serve as the key catalyst for the corporate transition from clinical stage to that of a revenue generating entity.



Stemline

• India
• 1 - 100 Employee

• Chief Commercial Officer (CCO)

  • Sep 2016 - Dec 2021

  Fully responsible for leading the transformation of Stemline from a clinical-stage entity to one with a full commercial capability and infrastructure. Established high-performing Marketing, Diagnostics, Sales, Access & Reimbursement, Operations and Medical Affairs functions for the successful launch of ELZONRIS® (tagraxofusp) in an ultra-orphan hematologic malignancy. Per ZS Associates independent Bloomberg data analysis, responsible for the number one ranked first-time commercial launch out of 72 biotechnology-sector organizations as measured by company stock value increase as a percentage. Show less



Baxalta

• United States
• Biotechnology
• 200 - 300 Employee

• Global Product Strategy Lead, Oncology

  • 2015 - 2016

  Headed up the development and execution of the go to market strategy for the global launch of pacritinib in myelofibrosis. Developed the asset’s life cycle strategy to expand labeled indications to both solid and hematologic malignancies via a multifactorial analytics process. • Served as Chair for the Joint Commercialization Committee (JCC) with co-promotion partner to foster a strong and productive alliance. Headed up the development and execution of the go to market strategy for the global launch of pacritinib in myelofibrosis. Developed the asset’s life cycle strategy to expand labeled indications to both solid and hematologic malignancies via a multifactorial analytics process. • Served as Chair for the Joint Commercialization Committee (JCC) with co-promotion partner to foster a strong and productive alliance.



Senior Vice President, Oncology

• Strategic Consultant

  • 2010 - 2015

  Retained to remove or mitigate impediments to market growth that render a brand to underperform. Implemented operational plans that drove clinical utility and brand uptake to 10 brands in early stage development, 15 brands in active launch mode, and 12 brands in orphan/rare disease. • Based on discovered key insights, advised a top tier pharmaceutical company during late stage due diligence to change corporate direction of an acquisition of a phase 3 asset. Recommendations led to the abandoning of the deal and reallocating $150MM+ investment to an internal asset. Show less



Pfizer

• Events Services
• 1 - 100 Employee

• Senior Director/Team Lead, Global Commercial Strategy, Oncology

  • 2007 - 2010

  Prepared and delivered launch readiness in 66 global markets while producing a successful on-time, first-in-class product launch. Developed and led the execution of short and long-term global marketing strategy for Torisel® (temsirolimus) in Mantle Cell Lymphoma and Renal Cell Carcinoma. • Rated above to significantly above expectations for comprehensive launch performance of Torisel in 66 countries worldwide. Prepared and delivered launch readiness in 66 global markets while producing a successful on-time, first-in-class product launch. Developed and led the execution of short and long-term global marketing strategy for Torisel® (temsirolimus) in Mantle Cell Lymphoma and Renal Cell Carcinoma. • Rated above to significantly above expectations for comprehensive launch performance of Torisel in 66 countries worldwide.



GlaxoSmithKline

• United States
• Investment Management

• Global Commercial Strategist (Oncology)

  • 2005 - 2007

  Developed the global commercial strategy for emerging oncology assets from candidate selection through phase 3. Produced effective target product profiles, trademarks and operative communications planning. • Collaborated with top academia to produce informed clinical trial design, and protocols which resulted in delivering differentiated products to the market. Recipient of three individual R&D awards. Developed the global commercial strategy for emerging oncology assets from candidate selection through phase 3. Produced effective target product profiles, trademarks and operative communications planning. • Collaborated with top academia to produce informed clinical trial design, and protocols which resulted in delivering differentiated products to the market. Recipient of three individual R&D awards.



AstraZeneca

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Manager/Training Lead, Oncology

  • 2003 - 2005

  Orchestrated and led the development of comprehensive launch training programs for new product introductions. Delivered an improved overall competency and effectiveness for AstraZeneca’s oncology sales force for brands treating breast cancer, NSCLC, and prostate cancer. • Blended a fragmented team of field and HQ-based trainers to establish one high performing cohesive team. Enhanced team environment led to innovative training programs which advanced sales force effectiveness.

• Senior Product Manager, Oncology

  • 2001 - 2003

  Led promotional efforts related to all brands in the breast cancer franchise. Established actionable product positioning strategies to maximize AstraZeneca’s breast cancer franchise presence in the US Market. • Recipient of the 2002 Gold Brand Team award from Product Management Today publication.

• Senior Promotions Manager, Gastroenterology, Respiratory & Cardiovascular

  • 2000 - 2001

  Developed regionally based brand promotional plans by identifying market needs and implementing corresponding operational plans. Developed promotional strategies and tactics which complemented U.S. brand teams’ activity for enhanced communication of brand messaging.• Boosted launch effectiveness of Nexium® by identifying gaps in market penetration. As a result, increased reach to highly ranked physicians in which the sales force had no access.